

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 July 2005 (14.07.2005)

PCT

(10) International Publication Number  
**WO 2005/063745 A3**

(51) International Patent Classification:

*C07D 471/10* (2006.01) *A61P 9/00* (2006.01)  
*A61K 31/40* (2006.01) *A61P 25/00* (2006.01)  
*A61K 31/47* (2006.01) *G01N 33/94* (2006.01)

(21) International Application Number:

PCT/US2004/043609

(22) International Filing Date:

22 December 2004 (22.12.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/532,546 23 December 2003 (23.12.2003) US  
60/539,554 26 January 2004 (26.01.2004) US  
60/565,251 23 April 2004 (23.04.2004) US

(71) Applicant (for all designated States except US): **ARENA PHARMACEUTICALS, INC.** [US/US]; 6166 Nancy Ridge Drive, San Diego, CA 92121-3223 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BOATMAN, Douglas, P.** [US/US]; 8839 Menkar Road, San Diego, CA 92126 (US). **ADAMS, John, W.** [US/US]; 3967 Lamont Street, No. 1, San Diego, CA 92109 (US). **MOODY, Jeanne, V.** [US/US]; 8148 Genesee Avenue, No. 57, San Diego, CA 92122 (US). **BABYCH, Eric, D.** [US/US]; 8840 Costa Verde Blvd., No. 3424, San Diego, CA 92122 (US). **SCHRADER, Thomas, O.** [US/US]; 7556 Charmant Drive, No. 1720, San Diego, CA 92122 (US).

(74) Agents: **SPRUCE, Lyle et al.**; Arena Pharmaceuticals, Inc., 6166 Nancy Ridge Drive, San Diego, CA 92121-3223 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:





- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

16 March 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF



(57) Abstract: The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (e.g., indazoles and benzothiazoles) which act as ligands for the  $\alpha 7$  nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof. Formulas (I, II, III, IV).

WO 2005/063745 A3